Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

Active, not recruiting · Phase 4 · NCT06572228

Conditions: Asthma

Research payments reported, 2025: $1.7M
U.S. investigators named: 54
Sites paid: 45
Planned or actual enrollment: 120

About the trial

Sponsor: Regeneron Pharmaceuticals (with Sanofi)
Tested: dupilumab (drug), Matching Placebo (drug), ICS/LABA (drug)
Dates: Started 2024-08-26; completion 2027-04-24
Results posted: Not yet

This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe. Uncontrolled asthma means that patients are still having frequent symptoms while taking their current asthma medication. The aim of the study is to see which regimen is more effective: taking dupilumab with an inhaled asthma medication or only taking a higher dose of the inhaled asthma medication. The type of asthma medication that will be used is a combination inhaled corticosteroid and long-acting beta-agonist (referred to as an ICS/LABA). Some patients may also receive an additional as…

From ClinicalTrials.gov, last updated 2026-05-22. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Regeneron Pharmaceuticals, Inc. reported $1.7M in research payments for this study in 2025 (1,393 payments).

Products named: Dupixent

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Crn Clinical Research Network LLC $235,395
Kern Research Inc $117,643
University of Michigan Health System, MI $66,903
Allergy Asthma & Clinical Research Center $60,491
Northwestern University $57,823
Washington University $54,880
Henderson Clinical Trials LLC $51,185
Shapero PAul Alan MD $50,102
Clinical Site PArtners Inc $48,240
University of Kansas Medical Center Research Institute Inc $46,783
Sneeze Wheeze & Itch Associates LLC $42,254
Treasure Valley Medical Research LLC $41,622
Metroplex Pulmonary and Sleep Center PA $37,377
National Jewish Health, CO $37,122
Intermountain Health Mckay-Dee Hospital, UT $36,952
Orso Health Inc $35,959
Clinical Research Specialists LLC $34,533
Feinstein Institute $33,760
Cincinnati Children's Hospital Medical Center, OH $33,535
St Francis Medical Institute $31,423
Ark Clinical Research LLC $30,851
Inova Fairfax Hospital, VA $29,183
Massachusetts General Hospital, MA $28,972
Montana Medical Research Inc $28,107
Henry Ford Health Hospital, MI $27,800
Lankenau Institute for Medical Research $27,450
Allianz Research Institute Inc $26,265
Allergy and Asthma Care of Waco $25,023
Elligo Health Research Inc $20,821
New York Medical College $20,535
Raffi Tachdjian $19,646
Newportnativemd MD Inc $19,486
The Lung and Sleep Research Institute of North Texas $19,255
Fundacion De Investigacion De Diego $19,041
University of Pittsburgh Physicians $19,000
Allergy & Asthma Specialists Psc $18,766
Rochester General Hospital $17,535
Northshore University Healthsystem - Evanston Hospital, IL $16,535
Premier Pulmonary Critical Care and Sleep Medicine $16,525
Integrated Research of Inland Inc $15,293
The Vancouver Clinic Inc Ps $14,535
Dharma PA D B A Southwest Family Medicine Associates $14,248
Allergy and Asthma Associates Psc $12,114
Puerto Rico Consortium for Clinical Investigation Inc $10,089
Clinical Research Associates of Central PA LLC $7,910

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it